18672-02-1

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-2-quinazolinamine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its reactive nature allows for the creation of complex molecules that can be used in the development of new drugs.
Used in Chemical Research:
6-Chloro-2-quinazolinamine is used as a research compound in the field of organic chemistry. It serves as a starting material for the synthesis of other quinazoline derivatives, which can be further studied for their chemical properties and potential applications.
Used in Drug Development:
6-Chloro-2-quinazolinamine is used as a building block in the development of new drugs, particularly in the pharmaceutical industry. Its ability to form complex compounds makes it a valuable asset in the creation of novel therapeutic agents.
Used in Organic Synthesis:
6-Chloro-2-quinazolinamine is used as a reagent in organic synthesis, allowing for the formation of a wide range of quinazoline-based compounds. These compounds can be further modified and studied for their potential applications in various fields, including medicine and materials science.
Used in Material Science:
6-Chloro-2-quinazolinamine is used as a component in the development of new materials, such as polymers and coatings, that can benefit from the unique properties of quinazoline-based compounds. Its incorporation into these materials can lead to improved performance and functionality.

Upstream product

• 1810-72-6 2,6-dichloroquinoline 
• 60-35-5 acetamide 
• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 1334594-87-4 C₉H₅ClN₂O₂ 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

One-pot synthesis of 2-aminoquinoline-based alkaloids from acetonitrile

α-Diaminoboryl carbanions, readily prepared from acetonitrile, stereoselectively convert 2-nitrobenzaldehydes into nitrophenyl (Z)-acrylonitriles. Subsequent reductive cyclization leads to a series of 2-aminoquinoline derivatives. The entire procedure is practically operated in a single flask.

Identification and specificity studies of small-molecule ligands for SH3 protein domains

The Src Homology 3 (SH3) domains are small protein-protein interaction domains that bind proline-rich sequences and mediate a wide range of cell-signaling and other important biological processes. Since deregulated signaling pathways form the basis of many human diseases, the SH3 domains have been attractive targets for novel therapeutics. High-affinity ligands for SH3 domains have been designed; however, these have all been peptide-based and no examples of entirely nonpeptide SH3 ligands have previously been reported. Using the mouse Tec Kinase SH3 domain as a model system for structure-based ligand design, we have identified several simple heterocyclic compounds that selectively bind to the Tec SH3 domain. Using a combination of nuclear magnetic resonance chemical shift perturbation, structure-activity relationships, and site-directed mutagenesis, the binding of these compounds at the proline-rich peptide-binding site has been characterized. The most potent of these, 2-aminoquinoline, bound with Kd = 125 μM and was able to compete for binding with a proline-rich peptide. Synthesis of 6-substitued-2- aminoquinolines resulted in ligands with up to 6-fold improved affinity over 2-aminoquinoline and enhanced specificity for the Tec SH3 domain. Therefore, 2-aminoquinolines may potentially be useful for the development of high affinity small molecule ligands for SH3 domains.